AddedRisk Factors
third-party vendors’ information systems from malicious third parties or insider threats may incorporate widely varying and frequently changing tactics, which may be enhanced or facilitated by artificial intelligence. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients’ personal data could result in significant liability under state (e.g., state breach notification laws), federal (e.g., HIPAA, as amended by HITECH), and international law (e.g., the EU General Data Protection Regulation, or GDPR) and may cause a material adverse impact to our reputation, affect our ability to use collected data, conduct new studies and potentially disrupt our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
The GDPR also imposes strict rules on the transfer of personal data to countries outside of the UK and EEA that do not ensure an adequate level of protection, including the United States in certain circumstances, unless derogation exists or a valid GDPR transfer mechanism (for example, the European Commission approved Standard Contractual Clauses (SCCs) and the UK International Data Transfer Agreement or Addendum (UK IDTA)) have been put in place, and transfer impact assessments conducted. The EU and U.S. have adopted its adequacy decision for the EU-U.S. Data Privacy Framework, or Framework, which entered into force on July 11, 2023. This Framework provides that the protection of personal data transferred between the EU and the United States is comparable to that offered in the EU. This provides a further avenue to ensuring transfers to
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
the United States are carried out in line with GDPR. There has been an extension to the Framework to cover UK transfers to the United States. The Framework could be challenged like its predecessor frameworks. Any inability to transfer personal data from the UK or EEA to the United States in compliance with data protection laws may impede our operations and may adversely affect our business and financial position.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
The UK’s data protection regime is independent from but aligned to the EU’s data protection regime. Although the UK is regarded as a third country under the EU’s GDPR, the European Commission has now issued an adequacy decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. In December 2025, the European Commission adopted a decision to extend the validity of the UK adequacy decision for six years until December 2031, determining that the UK continues to offer a level of data protection that is “essentially equivalent” to the EU standards. This follows the UK’s adoption of the Data (Use and Access) Act 2025 (the “DUAA”) on 19 June 2025. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK Government has confirmed that personal data transfers from the UK to the EEA remain free flowing. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, complexity and cost to our handling of personal data and our privacy and data security compliance programs and could require us to implement different compliance measures for the UK and the EEA.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our success is dependent on our executive management team’s ability to successfully pursue business development, strategic partnerships and investment opportunities as our company matures. We may also form or seek strategic alliances or acquisitions or enter into additional collaboration and licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances, acquisitions or licensing arrangements.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The USPTO and foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition,
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
and KYMERA THERAPEUTICS are now registered or allowed in the United States and have proceeded to registration in the European Union.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The intellectual property landscape relevant to our product candidates and programs is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
In our ongoing efforts to innovate and develop product candidates, we have integrated artificial intelligence (“AI”) and machine learning into virtual screening, hit validation and optimization technologies. While AI and machine learning presents opportunities for enhanced productivity and innovation, it also introduces inherent risks, including legal and regulatory, that could adversely impact our business and reputation. Proper use of AI and machine learning can lead to improved decision-making, cost reduction, and competitive advantage. However, improper use, including algorithmic biases, ethical considerations, data privacy issues, and potential regulatory non-compliance, could result in reputational damage, legal liabilities, and financial losses. The rapidly evolving regulatory landscape surrounding AI also poses a risk, as new laws and regulations could impose additional compliance burdens, resulting in increased operational costs to comply with U.S. and non-U.S. laws concerning the use of AI, the nature of which cannot be determined at this time. In addition, the European Union recently passed the Artificial Intelligence Act, whose regulations will be developed over the coming year and, in the U.S., the recent Executive Order concerning artificial intelligence may result in extensive new federal rule-making. We are committed to implementing governance and control mechanisms to mitigate these risks, but there can be no assurance that such measures will adequately prevent or mitigate the adverse effects that the integration and use of AI may have on our business, financial condition, and results of operations.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
If a prolonged government shutdown occurs, shut down occurs again or if the FDA, NIH, SEC or the USPTO experiences significant decreases in funding or personnel, it could significantly impact the ability of the FDA to issues licenses needed for conduct of our clinical trials, the NIH to conduct research or provide grants, and the abilities of the FDA and the USPTO to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have entered into a collaboration and licensing arrangement with Sanofi with respect to our IRAK4 program and Gilead with respect to our CDK2 program and we may in the future form or seek strategic alliances or acquisitions, create joint ventures, or enter into additional collaboration and licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our current product candidates and any future product candidates that we may develop.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Recently, there has been legislation proposed that, if enacted, BIOSECURE-related restrictions, and any future legislative, regulatory, or administrative actions expanding or modifying these restrictions, could negatively impact U.S. companies and institutions that accept U.S. funding for projects that utilize biotechnology equipment and or services produced or provided by certain biotechnology providers having relationships with foreign adversaries and which pose a threat to national security. adversaries.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above, as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
S. policy occurred and since Since the start of the Trump Administration current administration in 2025, U.S. policy changes there have been implemented at a rapid pace significant changes to U.S. trade, healthcare, immigration and government regulatory policy and additional changes are likely.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
With the change in presidential administrations in 2025, there There is substantial uncertainty as to how, if at all, whether and how the new current administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. candidates and any products for which we obtain approval.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Though we do not currently receive U.S. government funding, BIOSECURE-related restrictions could indirectly affect our collaborators, customers, investors, or suppliers that receive U.S. government funding, and we are currently evaluating steps to mitigate any potential impact of any future stricter expanded or modified legislation towards or regulatory or administrative actions applicable to foreign entities providing services to U.S. based companies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We Like other companies in our industry, we and certain of our service providers have experienced and may in the future experience cyberattacks. cyberattacks and other attempts to disrupt or gain unauthorized access to our and our third-party vendors’ information systems.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in preclinical studies, (i) studies KT-621 demonstrated full inhibition of IL-4/IL-13 pathway in all relevant human cell contexts with picomolar potency that was superior to exceeded published data for dupilumab, and equivalent or superior activity to dupilumab, and (ii) KT-295 demonstrated picomolar to nanomolar potencies across all relevant human cell types evaluated. dupilumab.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Through Further, through executive and legislative action, the federal government has also taken steps to restrict restricts data transactions involving certain sensitive data categories – including health data, genetic data, and biospecimens – with persons affiliated with China, Russia, and other countries of concern. concern, including through the Department of Justice’s January 8, 2025, rule on “Preventing Access to U.S.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Though we do not currently receive U.S. government funding, we are currently evaluating We regularly evaluate steps to mitigate any potential impact of any future stricter expanded or modified legislation or regulatory or administrative actions towards foreign entities providing services to U.S. based companies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We do not expect to generate revenue from product sales unless and until we can advance and complete the development of, obtain marketing approval for, and begin to sell, one or more of our product candidates.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In particular, while we have conducted certain preclinical studies of KT-621 and KT-295, KT-579, we do not know whether either any of these product candidates will perform in our planned clinical trials as it has performed in these prior preclinical studies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The number of patients for our product candidates in the United States and elsewhere may turn out
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We face an inherent risk of product liability exposure related to the testing of our current or future product candidates in human clinical trials and will face an even greater risk if we commercially sell any current or future product candidates that we may develop.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 7, 2020, we entered into a collaboration agreement, or the Original Sanofi Agreement, with Genzyme Corporation, a subsidiary of Sanofi, to co-develop drug candidates directed to two biological targets. The Original Sanofi Agreement became effective during the third quarter of 2020.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In December 2022, Sanofi provided us with written notice of its intention to take KT-474 into Phase 2 clinical trials. In the fourth quarter of 2023, we achieved two milestones of $40.0 million and $15.0 million relating to the dosing of the first patient in the Phase 2 clinical trial for the first and second indications, respectively. In the first quarter of 2025, we achieved a development milestone related to certain preclinical activities associated with the IRAK4 program. In connection with this milestone we unconstrained $20.0 million of consideration in the first quarter of 2025. All milestone payments have been received as of December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In June 2025, Sanofi communicated its decision to exercise its full participation election under the terms of the companies’ collaboration agreement, and to advance KT-485/SAR447971, into clinical testing. As a result, Sanofi stopped development of KT-474. In connection with the IRAK4 program, we remain eligible to receive up to $975 million in development and commercial milestones upon the achievement of certain developmental or regulatory events and upon the achievement of certain net sales thresholds.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On June 25, 2025, we entered into an exclusive option and license agreement (the “Gilead Agreement”) with Gilead Sciences, Inc. (“Gilead”), to collaborate on developing novel molecular glue degraders directed against cyclin-dependent kinase 2 (“CDK2”). Under the Gilead Agreement, the Company granted to Gilead an exclusive option, exercisable during a defined option period, to exercise an exclusive, worldwide license to develop, manufacture, and commercialize certain CDK2 degraders generated under the collaboration.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Pursuant to the Gilead Agreement, we are responsible for all discovery and preclinical research activities through the delivery of a complete data package as defined in the agreement. If, after receiving the complete data package, Gilead exercises its option to license the program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
If Gilead does not exercise the option during the option period defined in the agreement, then the Gilead Agreement will terminate. Following option exercise, the Gilead Agreement will expire on a product-by-product and country-by-country basis upon the expiration of all royalty obligations under the agreement. Gilead may terminate the agreement for convenience upon advance written notice. Each party may also terminate the agreement for material breach, insolvency, and the agreement may be terminated for certain other customary reasons, including Gilead’s right to terminate certain provisions of the agreement following a change of control of our company.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
As of December 31, 2025, we had outstanding pre-funded warrants to purchase 15,815,253 shares of common stock, each with an exercise price of $0.0001 per share. These warrants can be exercised at any time at the discretion of the holders, subject to certain ownership limitations. While the potential exercise of these pre-funded warrants would result in the issuance of additional shares, thus increasing the total shares outstanding, their nominal exercise price means they are already considered outstanding for purposes of calculating our weighted average common stock outstanding and earnings per share. Due to the minimal exercise price, we do not anticipate significant additional cash proceeds upon exercise and consequently does not expect the exercise of these warrants to materially affect its liquidity, capital resources, or overall financial condition.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We have performance conditions included in certain of our restricted stock units and stock options that are based upon the achievement of pre-specified clinical development milestones. As the outcome of each event has inherent risk and uncertainties, and a positive outcome may not be known until the event is achieved, we begin to recognize the grant-date fair value of the performance-based restricted stock awards when we determine the achievement of each performance condition is deemed probable, a determination which requires significant judgment by management. On the date the performance condition is deemed probable, we record a cumulative expense catch-up, with remaining expense amortized over the remaining service period. We reassess the probability of achievement at each reporting period and adjust cumulative expense as necessary.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
Additionally with respect to Sanofi, on December 2, 2022, Sanofi provided the Company with written notice of its intention to advance the collaboration target 1 candidate, KT-474, into Phase 2 clinical trials for which the Company received milestone payments as further set forth in the Amended Sanofi Agreement. Phase 2 clinical trials of KT-474 are initially investigating its potential in HS and AD with the clinical trial for both indications having been initiated and commenced dosing in 2023.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
IRAK4 STAT6 $ 13,762 86,615 $ 17,850 39,805 $ (4,088) STAT3 11,490 8,332 3,158 MDM2 8,170 11,823 (3,653) 46,810 Other 61,278 51,388 9,890 92,165 84,981 7,184 Research and development compensation and related personnel expense 65,039 55,751 9,288 90,346 75,975 14,371 Research and development overhead and administrative costs 29,342 19,104 10,238 47,442 39,487 7,955 Total research and development expenses $ 189,081 316,568 $ 164,248 240,248 $ 24,833 76,320
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase of $51.2 $76.3 million was primarily due to an increase of $58.4 $46.8 million in costs related to our STAT6, TYK2 STAT6 program, and MDM2 programs, as well as an increase increases of $21.1 $14.4 million and $8.0 million, respectively, in personnel, personnel and stock-based compensation compensation, and occupancy and overhead costs due to increases in employee headcount in our research and development functions. headcount.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
IRAK4 STAT6 $ 13,762 39,805 $ 17,850 — $ (4,088) STAT3 11,490 8,332 3,158 MDM2 8,170 11,823 (3,653) 39,805 Other 61,278 51,388 9,890 84,981 94,700 (9,719) Research and development compensation and related personnel expense 75,975 65,039 55,751 9,288 10,936 Research and development overhead and administrative costs 39,487 29,342 19,104 10,238 10,145 Total research and development expenses $ 240,248 $ 189,081 $ 164,248 $ 24,833 51,167
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase of $51.2 million was primarily due to an increase of $58.4 $30.1 million in costs related to our STAT6, TYK2 clinical and MDM2 preclinical programs, as well as an increase and increases of $21.1 $10.9 million and $10.1 million respectively in personnel, personnel and stock-based compensation costs, and occupancy and overhead costs due to increases in employee headcount in our research and development functions. headcount.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, net cash provided by financing activities was $608.9 $990.7 million, consisting of $547.9 $928.9 million in proceeds from issuance of common stock and accompanying pre-funded warrants, net of offering costs, $48.7 million in proceeds from the issuance of common stock through the Cowen Sales Agreement, net of issuance costs, $11.8 $61.6 million in proceeds from the exercise of employee stock options, $2.0 $1.7 million from proceeds from the employee stock purchase plan, partially offset by finance lease payments of $1.6 $1.5 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We Pursuant to the Sanofi Agreement, with respect to both targets we are responsible for discovery and preclinical research and conducting a phase 1 clinical trial for at least one degrader directed against IRAK4 plus up to three backup degraders. back up degraders, the costs of which will be borne by us, except in certain circumstances.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in revenue is primarily attributable to the achievement satisfaction of $55 million in milestones the performance obligation under the Sanofi agreement in the fourth second quarter of 2023 and 2025, offset by revenue related to the associated cumulative catch-up of revenue at that time. Gilead agreement.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We have In addition, pursuant to the Sanofi Agreement, Sanofi will grant to us an exclusive option, or Opt-In Right, exercisable exercisable, at our sole discretion, on a collaboration-target-by-collaboration-target collaboration target-by-collaboration target basis that will include the right to (i) to fund 50% of the United States development costs for collaboration products directed against such target in the applicable field of use and (ii) share equally in the net profits and net losses of commercializing collaboration products directed against such target in the applicable field of use in the United States.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development expenses were $316.6 million for the year ended December 31, 2025, compared to $240.2 million for the year ended December 31, 2024, compared to $189.1 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
General and administrative expenses were $68.2 million for the year ended December 31, 2025, compared to $63.5 million for the year ended December 31, 2024, compared to $55.0 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Other income, net was $38.0 million for the year ended December 31, 2025, compared to $37.8 million for the year ended December 31, 2024, compared to $18.6 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We will further be are also eligible to receive tiered royalties on net sales by Gilead ranging from the high single digits single-digit to high teens, mid-teen percentages, subject to low-single digits upward adjustments customary reductions in certain circumstances. circumstances
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
Patient access to therapy can also be a challenge, as biologics are can be more complex to prescribe and reimburse than small molecule medicines.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new